Skip to main navigation Skip to search Skip to main content

Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study

  • Paolo Boffano
  • , Anna Maria Agnone
  • , Francesca Neirotti
  • , Roberta Bonfiglio
  • , Matteo Brucoli
  • , Muhammad Ruslin
  • , Ana Durković
  • , Marija Milosavljević
  • , Vitomir Konstantinovic
  • , Juan Carlos de Vicente Rodríguez
  • , Tania Rodríguez Santamarta
  • , Christophe Meyer
  • , Aurelien Louvrier
  • , Alexandre Michel-Guillaneux
  • , Eugenie Bertin
  • , Thomas Starch-Jensen
  • , Ana J. Tadic
  • , Branislav V. Bajkin
  • , Sophie Dugast
  • , Helios Bertin
  • Pierre Corre, József Szalma, Tadej Dovsak, Luka Prodnik, Radovan Mottl, Emil Dediol, Boris Kos, Adaia Valls Ontanon, Panagiotis Stathopoulos, Konstantina Tsekoura, Adam Polcyn, Adam Michcik, Linas Zaleckas, Nikolai Pavlov, Angel Sapundzhiev, Petar Uchikov, Petia Pechalova

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The purpose of this European multicenter study was to describe the general characteristics and risk factors of MRONJ lesions as well as their clinical diagnosis and management at different European Oral and Maxillofacial Surgery centers, in order to minimize selections biases and provide information about the epidemiology, etiopathogenesis, and the current trends in the treatment of MRONJ across Europe. Materials and methods: The following data were registered for each patient: gender; age at MRONJ diagnosis; past medical history; indication for antiresorptive or antiangiogenic therapy; type of antiresorptive medication; local risk factor for MRONJ; MRONJ Stage; anatomic location and symptoms; treatment; surgical complications; recurrence. Results: A total of 537 patients (375 females, 162 males) with MRONJ were included. Statistically significant associations were found between patients with metastatic bone disease and recurrences (P < 0.0005) and between advanced MRONJ stages (stages 2 and 3) and recurrences (P < 0.005). Statistically significant associations were also found between male gender and recurrences (P < 0.05), and between MRONJ maxillary sites and recurrences (P < 0.0000005). Conclusions: A longer mean duration of antiresorptive medications before MRONJ onset was observed in patients affected by osteoporosis, whereas a shorter mean duration was observed in all metastatic bone cancer patients, and in particular in those affected by prostate cancer with bone metastases or multiple myeloma. Surgery plays an important role for the management of MRONJ lesions.

Original languageEnglish
Article number101931
JournalJournal of Stomatology, Oral and Maxillofacial Surgery
Volume125
Issue number5
DOIs
Publication statusPublished - Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antiresorptive drugs
  • Epidemiology
  • MRONJ
  • Management
  • Osteonecrosis

Fingerprint

Dive into the research topics of 'Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study'. Together they form a unique fingerprint.

Cite this